Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus gefitinib in EGFR-positive advanced non-squamous NSCLC (real-world study)
ChiCTR2000039782Phase 4Recruiting
- Sponsor
- Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
- Start
- Nov 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and gefitinib in non-small cell lung cancer (NSCLC), sponsored by Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine. Primary endpoint: Progression-free survival (PFS). Started Nov 2020; status: recruiting.
02
Drugs
Rivoceranibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039782.